Table 2.
Immunologic data in patient 1 and our cost of immune monitoring and desensitization therapy
| Patient 1 | Before desensitization | After desensitization |
| With wife donor | ||
| DSA (MFI) | A24-4924, B58-9767, DR11-13112, DR17-13598, DQ7-13194, DQ2-14751 | A24-1000, B58-7055, DR11-4296, DR17-1925, DQ7-11838, DQ2-2410 |
| AHG-CDC LCM (%) | 80 | 20 |
| T FCM (MCS) | 212 | Negative |
| B-FCM (MCS) | 504 | 328 |
| With KPD donor | ||
| DSA (MFI) | B8, 6830: DR 17, 14751: DQ2, 13112 | B8, 2400: DR 17, 1925: |
| DQ2, 2410 | ||
| AHG-CDC (%) | 20 | 17 |
| T-FCM (MCS) | 88 | Negative |
| B-FCM (MCS) | 335 | 190 |
| The cost of immune monitoring and desensitization therapy (USD) | ||
| AHG-CDC LCM | 20 | |
| T and B FCM | 100 | |
| DSA ( Luminexx, qualitative) | 40 | |
| DSA ( Luminexx, quantitative) | 425 | |
| HLA (class 1 and 2) | 200 | |
| Plasmapheresis | 300 | |
| Bortezomib (Baximib, Ranbaxy) 2 mg | 60 | |
| IVIg (Plasmaglob, Plasmagen) 5 gm | 125 | |
| Rabbit anti-human thymocyte immunoglobulin (Thymoglobulin, Genzyme-Sanofi) 25 mg | 200 | |
| Valganciclovir (Cymgal, Biocon) 450 mg | 3 | |
| Methyl prednisolone ( Solumedrol, Pfizer) 125 mg | 4 | |
DSA: Donor specific antibody; AHG-CDC-LCM: An anti-human, globulin-enhanced, complement-dependent cytotoxicity lymphocytotoxicity cross matches; FCM: Flow cross match; MCS: Median channel shift; MFI: Mean fluorescent intensity; KPD: Kidney paired donation.